Premium
Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma
Author(s) -
Patrinely James R.,
Baker Laura X.,
Davis Elizabeth J.,
Song Haocan,
Ye Fei,
Johnson Douglas B.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32984
Subject(s) - medicine , ipilimumab , oncology , melanoma , neuroblastoma ras viral oncogene homolog , nivolumab , cancer , tumor progression , progression free survival , immunotherapy , chemotherapy , cancer research , colorectal cancer , kras
Background Greater than one‐half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti–PD‐1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti–PD‐1 therapy. Methods The authors evaluated 383 consecutively treated patients who received anti–PD‐1 for advanced melanoma between 2009 and 2019. Patient and disease characteristics at baseline and at the time of progression, subsequent therapies, objective response rate (ORR), overall survival, and progression‐free survival were assessed. Results Of 383 patients, 247 experienced disease progression. The median survival after progression was 6.8 months. There was no difference in survival noted after disease progression based on primary tumor subtype, receipt of prior therapy, or therapy type. However, significantly improved survival after disease progression correlated with clinical features at the time of progression, including normal lactate dehydrogenase, more favorable metastatic stage (American Joint Committee on Cancer eighth edition stage IV M1a vs M1b, M1c, or M1d), mutation status ( NRAS or treatment‐naive BRAF V600 vs BRAF / NRAS wild‐type or treatment‐experienced BRAF ‐mutant), decreasing tumor bulk, and progression at solely existing lesions. After progression, approximately 54.3% of patients received additional systemic therapy. A total of 41 patients received BRAF/MEK inhibition (ORR of 58.6%, including 70.4% for BRAF/MEK‐naive patients), 30 patients received ipilimumab (ORR of 0%), and 11 patients received ipilimumab plus nivolumab (ORR of 27.3%). Conclusions The current study identified prognostic factors in advanced melanoma for patients who experienced disease progression while receiving anti–PD‐1, including lactate dehydrogenase, stage of disease, site of disease progression, tumor size, and mutation status.